MAR 31·TipRanks→
Pliant Therapeutics Launches New $50 Million ATM Program
Pliant Therapeutics (PLRX) has launched a new $50 million "at-the-market" equity program with Leerink Partners, allowing the company to sell common stock to raise capital. This new program replaces a prior 2021 agreement with Cantor Fitzgerald & Co., which was terminated without penalty and with no shares sold. An analyst rating on PLRX stock is currently Hold with a $1.00 price target, and TipRanks' AI Analyst, Spark, rates the stock as Neutral due to weak financial performance despite some short-term momentum.
MAR 18·Bitget▲
Clinical Progress and Disclosure Timeline: Biopharmaceutical company Pliant Therapeutics (NASDAQ: PLRX) announced that Phase I clinical trial data for its solid tumor candidate drug Pln-101095 will be officially released at the 2026 American Association f
Pliant Therapeutics (NASDAQ: PLRX) is set to release Phase I clinical trial data for its solid tumor drug candidate, Pln-101095, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. This disclosure will detail the drug's safety, tolerability, and preliminary efficacy in advanced solid tumor patients, particularly those with liver or pancreatic cancer. Positive early data could act as a catalyst for the biotech company's stock, though investors should monitor subsequent clinical progress.
